7 Analysts Assess Novo Nordisk: What You Need To Know
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have rated Novo Nordisk (NVO) as somewhat bullish, with recent ratings showing a positive trend. The average 12-month price target for NVO is now $130.71, marking a 16.19% increase from the previous target of $112.50. Novo Nordisk, a leader in diabetes care, has shown strong financial performance with a revenue growth of 36.95%, a net margin of 33.35%, and an ROE of 22.01%. Analysts' actions and price target adjustments reflect their optimistic outlook on the company's future performance.
February 20, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
7 analysts have recently rated Novo Nordisk as somewhat bullish, with an updated average 12-month price target of $130.71, reflecting a 16.19% increase. The company's strong financial performance and market leadership in diabetes care are likely factors in this positive outlook.
The unanimous somewhat bullish rating from analysts, combined with the significant increase in the average price target, suggests a strong positive sentiment towards Novo Nordisk. The company's impressive financial performance and dominant position in the diabetes care market likely contribute to this outlook. Given these factors, the short-term impact on NVO's stock price is expected to be positive.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100